Company ProfilePremium

Anterogen.Co., Ltd.

Company Profile Analysis

Ticker: 065660.KQ주식회사 안트로젠

ESOMAR 23 Corporate BadgeISO Certifications Badge
Anterogen.Co., Ltd. - Company showcase

Year Founded & Workforce

2000

35 Employees

Anterogen.Co., Ltd. logo

Anterogen.Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Anterogen.Co., Ltd. Overview

Anterogen is a Seoul-based adult stem-cell company. It was among the first organisations anywhere to bring adipose-derived mesenchymal stem cell (ASC) products to market: Queencell, an autologous stromal-vascular-fraction product approved in 2010, and Cupistem, approved in January 2012 for Crohn's fistula and described as the world's first approved ASC therapy.

Neither domestic product scaled commercially. Queencell's licence was withdrawn in 2026, and Cupistem now generates negligible sales. Current revenue depends mainly on the in-licensed pulmonary arterial hypertension drug Remodulin.

The investment case therefore rests on the company's allogeneic, off-the-shelf, cryopreservable ASC hydrogel sheet platform (ALLO-ASC-Sheet). Japan approved it in April 2026, as "Allostem", for epidermolysis bullosa through licensee Ishin Pharmaceutical. It launched in Japan on 27 July 2026, with Anterogen acting as exclusive manufacturer and supplier.

The second major use of the platform, diabetic foot ulcer, has failed two efficacy readouts. Anterogen is a pre-profitability, low-leverage, equity-funded biotech. Its value now hinges on Japanese Allostem uptake and on ex-Japan expansion.


What the company does

Anterogen researches, develops, manufactures and sells cell-therapy products and orphan drugs based on adult stem cells, chiefly adipose tissue-derived MSCs. It also sells stem-cell-conditioned-media cosmetics and provides stem-cell banking and analytical testing services.

Its commercial and development portfolio has three layers:

  1. Approved autologous cell therapies (Korea).

    • Cupistem (autologous ASC injection for Crohn's fistula; MFDS approval January 2012; HIRA reimbursement January 2014).

    • Queencell (autologous adipose SVF for subcutaneous tissue defects; MFDS approval March 2010; licence withdrawn 2026).

    • Adipocell (for depressed scars) is cited in company materials as an earlier product.

  2. Allogeneic off-the-shelf platform (ALLO-ASC). A hydrogel sheet carrying about 1 million donor-derived ASCs per 5×5 cm sheet. It is cryopreservable for about one year and "ready-made" (no patient-specific culture is needed). Applications:

    • Epidermolysis bullosa (Allostem; approved in Japan in 2026)

    • Diabetic foot ulcer

    • Burns

    • Crohn's disease (injectable)

    • Knee osteoarthritis (ANT-301)

  3. Non-cell assets.

    • In-licensed Remodulin (treprostinil) injection for pulmonary arterial hypertension, which is currently the main revenue source.

    • A small-molecule herpes zoster antiviral (ANT-501), obtained through the 2022 merger with CSK.

    • Cosmetics: SCM2 and SCM2-Black hair care; Therastem-Derma, Therastem-White Silk and Therastem-White Glutathione skin care; and a "stem cell media program set" cosmetic raw material.

    • Services: stem-cell banking, and sample analysis for clinical studies (identity, purity, potency and adventitious-virus testing).

Business and revenue model

Revenue streamModelStatus (Oct 2026)Source
Remodulin injectionIn-licensed product distribution in KoreaDescribed in June 2026 press as effectively the sole meaningful revenue sourceMedisobizanews, 15 Jun 2026
CupistemOwn-product sales; reimbursed (ceiling price KRW 13.49M per treatment, 2014)Negligible current salesBiospectator, 2014; Medisobizanews, 2026
QueencellOwn-product salesLicence withdrawn (June 2026)Medisobizanews, 15 Jun 2026
Allostem (ALLO-ASC-EB) supply to IshinFinished-product supply, plus milestones and a royalty (about 9% of sales, per 2019 press)First commercial shipment July 2026eToday, 2019; Medical Daily, Jul 2026
Licensing incomeUpfront and milestone payments from Ishin (EB, DFU and burns licences, Japan/Taiwan)KRW 3.8bn of upfront and milestones received by c.2016; later milestones NPDBiospectator, c.2016
CosmeticsProduct sales (B2C/B2B), raw materialOngoing; revenue NPDInvesting.com profile
ServicesStem-cell banking and analytical testingOngoing; revenue NPDInvesting.com profile

Mix by type. Product sales (distribution plus own products) dominate. Licensing is episodic. There is no subscription revenue. A product-by-product revenue split for FY2023–FY2025 is NPD in the sources reviewed.

Value-chain position. For Allostem, Anterogen is a vertically integrated originator and contract manufacturer:

  • It holds the cell banks.

  • It manufactures at its Gasan and Magok GMP sites, both accredited by Japan's PMDA as Foreign Manufacturers in March 2025.

  • It ships finished sheets to Ishin, which holds the Japanese marketing authorisation, carries out commercialisation and holds Taiwan rights.

In Korea, the company sells directly and distributes Remodulin.

Customers and end markets.

  • Hospitals treating rare and severe dermatological diseases: EB in Japan.

  • Gastroenterology and colorectal surgery: Crohn's fistula.

  • Pulmonary hypertension centres: Remodulin.

  • Wound-care settings: DFU, investigational.

  • Orthopaedics: osteoarthritis, investigational.

  • Consumers: cosmetics.

In its IR materials the company describes itself as a bio-venture for "human tissue regeneration" specialising in cell therapies and orphan drugs using adult stem cells. Its founder has framed the strategy as targeting niche rare-disease markets in Japan, the US and Europe that lack competitors, rather than large crowded indications (Biospectator interview, c.2016).

Independent characterisation. Anterogen is best understood as a single-platform, pre-scale rare-disease cell-therapy manufacturer whose domestic legacy products have failed commercially. A thin, low-margin distribution business partially covers fixed costs. The company holds a large equity cushion relative to its liabilities (equity of KRW 87.45bn against total assets of KRW 88.26bn at FY2025), but its operating cash burn is modest and its revenue base is very small.

The April 2026 Japanese approval is the company's first ex-Korea commercial validation. Its economic significance depends on uptake in a patient pool estimated at roughly 500–1,000 in Japan.

Strategy

Stated strategy (themes)

  1. Rare-disease niche focus. Target orphan indications with no effective treatment in Japan, the US and Europe, rather than large competitive markets (Lee Sung-gu, Biospectator, c.2016).

  2. Off-the-shelf allogeneic platform. Overcome the limits of autologous products (culture lead times of up to four weeks, short shelf life, high cost) with a cryopreserved, mass-producible, exportable ASC sheet (company IR; Biospectator).

  3. Partner-led regulatory approval, Anterogen-led manufacturing. Licensees such as Ishin run local development and approval, while Anterogen keeps manufacturing and supply economics plus milestones and royalties (Hankyung, Mar 2025).

  4. Japan first, then expansion. Use the Japanese approval as a foothold for two additional countries in Asia and Europe, and for the US through a Phase 2 EB programme (Medical Daily, Jul 2026; Biotimes).

  5. Pipeline diversification beyond cell therapy. Add a small-molecule antiviral (ANT-501) through the CSK merger and an osteoarthritis cell therapy (ANT-301) (Medisobizanews, 2026).

Strategic initiatives (last 24 months)

InitiativeDateDetailSource
PMDA Foreign Manufacturer AccreditationMar 2025Both the Gasan and Magok plants are cleared to supply JapanHankyung, Mar 2025
Japanese pre-NDA and NDA (via Ishin)Apr–Jul 2025Pre-NDA meeting (expected 16 Apr 2025); NDA filed 8 Jul 2025 with an expanded label (DEB, JEB, EBS)Hankyung; Daily Invest
PMDA GMP inspectionDec 2025Final pre-approval step; management said all requested supplements had been completedHankyung, Dec 2025
Japanese approval and pricingApr–Jul 2026Approval 3 Apr 2026; insurance price set; launch 27 Jul 2026Hankyung; Medical Daily
Portfolio rationalisationJun 2026Queencell licence withdrawnMedisobizanews
ANT-301 progression2,026Korea Ph1 safety confirmed; US IND under review; Ph2 start targeted within 2026Medisobizanews; Medical Daily
ANT-5012,026Ph1 IND targeted for 2026Chickstock IR summary
National R&D projects2,025Government projects on knee OA, stem-cell therapy and 3D culture (12 national R&D projects in total)THE VC

ESG commitments and cost programmes

No formal ESG commitments or cost-reduction programme with targets were found. Headcount fell from 43 (FY2022) to 29 (FY2024) without an announced programme.

Medium-term guidance

ItemTimelineSource
Japanese launchJuly 2026 (achieved)IR, Mar 2026
Additional country launchesTwo more countries in Asia and EuropeMedical Daily, Jul 2026
ANT-301 Phase 2Within 2026Medical Daily, Jul 2026
ANT-501 Phase 1 IND2,026IR, Mar 2026

Anterogen does not publish quantitative financial guidance. Operational timelines it has communicated:

Products & Services

Marketed and formerly marketed products

ProductType / descriptionIndicationKey specifications / evidenceTarget customerApproval / launchPricingStatusSource
Allostem (ALLO-ASC-EB; ALLO-ASC-Sheet)Allogeneic adipose-derived MSC hydrogel sheet; off-the-shelf; cryopreservedDystrophic EB (DEB), junctional EB (JEB), severe EB simplex (Japan label)Applied weekly in trials; company reports a durable blister-free effect lasting years in some patients; approved as a designated regenerative medical productJapanese EB treatment centres via IshinJapan approval 3 Apr 2026; launch 27 Jul 2026Japanese insurance price about JPY 2,955,232 per set (2 vials). The company cites about USD 630,500 per patient per year at 26 vials (see note)Commercial in Japan; Korea Ph1/2 and US Ph2 ongoingHankyung, Apr 2026; IR, 16 Mar 2026 (via Chickstock); Medisobizanews
Cupistem injectionAutologous adipose-derived MSC injectionCrohn's fistula82% complete healing at week 8; 81% of those sustained at week 96 (company/MFDS summary). Dose 3×10⁷ cells/mL for fistula ≤1 cm; 6×10⁷ cells in 2 mL for 1–2 cmGastroenterology / colorectal surgery (Korea)MFDS Jan 2012; reimbursed Jan 2014Ceiling price KRW 13.49M (patient co-pay 10%), 2014Marketed; negligible sales (2026)MFDS; Biospectator; PMC review
QueencellAutologous adipose SVF (MSCs, preadipocytes, endothelial progenitors, pericytes and other cells), minimally manipulatedSubcutaneous adipose tissue defects1×10⁶ cells/mLAesthetic / reconstructiveMFDS Mar 2010NPDLicence withdrawn, Jun 2026MFDS; Medisobizanews
AdipocellAutologous adipose-cell productDepressed scars—DermatologyHistorical (date NV)NPDStatus NVAeroLeads company profile
Remodulin injectionTreprostinil (in-licensed)Pulmonary arterial hypertension—PAH centres (Korea)NPDNPDPrincipal revenue sourceInvesting.com; Medisobizanews

Note on Allostem economics: The company-cited annual cost of about USD 630,500 per patient (26 vials) cannot be reconciled with the disclosed price of about JPY 2,955,232 per two-vial set. Thirteen sets per year at that price is about JPY 38.4M, which is materially lower in USD terms. The basis of the company figure (FX rate, per-vial versus per-set pricing, or dosing assumption) is not disclosed in the public summary. Investors should rely on the official Japanese price listing.

Development pipeline

ProgrammeModalityIndicationStage (latest disclosed)Key data / eventsSource
ALLO-ASC-EBAllogeneic ASC sheetDEB/JEB/EBSJapan approved (Apr 2026); Korea Ph1/2; US Ph2; FDA orphan designationJapan Ph3 enrolled 6 patientsMedisobizanews, 2026; Edaily, 2022
ALLO-ASC-DFU (KR)Allogeneic ASC sheetDiabetic foot ulcer (Wagner 1–2)Ph3 DFU-301 failed (Jan 2022)No significant difference in complete wound closure at 12 weeks (mITT). The company attributed this to loss of cell potency during washing of animal-derived serumEdaily; Dailypharm
ALLO-ASC-DFU (KR)Allogeneic ASC sheet (xeno-free medium)DFU Wagner 2Ph3 DFU-302 (n=104) primary completion 5 Dec 2024; topline result NPD in sources reviewed. 24-month safety follow-up registeredCompany still described Korean Ph3 as "in progress" (Jun 2026)ClinicalTrials.gov; Medisobizanews
ALLO-ASC-Sheet (US)Allogeneic ASC sheetDFU Wagner 1 (DFU-102, n≈56)Ph2 failed (topline 31 Jan 2025)Complete closure at 12 weeks: 45.7% (ALLO-ASC) vs 60% (hydrogel control)Edaily, Feb 2025
ALLO-ASC-Sheet (US)Allogeneic ASC sheetDFU Wagner 2 (DFU-103, n≈64)Ph2 ongoing; FDA RMAT designation (DFU)—Edaily, 2025; IR, 2020
ALLO-ASC-BIAllogeneic ASC sheetDeep second-degree burnsPh2 completed (Jul 2021); no subsequent filing found—ClinicalTrials.gov NCT02619851
ALLO-ASC-CDAllogeneic ASC (injectable)Crohn's diseaseKorea Ph1—Medisobizanews, Jun 2026
ANT-301Allogeneic ASC (3D culture referenced in national R&D)Knee osteoarthritis (Kellgren-Lawrence 3–4)Korea Ph1 (ANT-301-102) safety confirmed in 6 subjects (Aug 2026); US IND under review; Ph2 planned within 2026Company-reported pain reduction of 44% at 24 weeks (low dose) and 63% at 12 monthsKormedi; Chickstock IR summary; Medical Daily
ANT-501Small-molecule antiviral (from CSK merger)Herpes zosterPreclinical; Ph1 IND targeted for 2026Company claims about 750× the antiviral potency of acyclovir (preclinical)Chickstock IR summary; Medisobizanews
Herpes simplex programmeAntiviralHerpes simplexEarly (2023 IR mention)—Company IR, May 2023

Cosmetics and raw materials

ProductCategoryDescriptionSource
SCM2Hair careStem-cell-conditioned-media hair productInvesting.com profile
SCM2-BlackHair careLine extensionInvesting.com profile
Therastem-DermaSkin careConditioned-media skin careInvesting.com profile
Therastem-White SilkSkin careBrightening lineInvesting.com profile
Therastem-White GlutathioneSkin careBrightening lineInvesting.com profile
Stem cell media program setCosmetic raw materialB2B ingredientInvesting.com profile

In 2023 management guided that hair-loss-mitigating functional cosmetics could reach about KRW 10bn in sales (Hankyung, Mar 2023). No subsequent disclosure confirms that level, and total company revenue has not exceeded KRW 8.1bn in any year since.

Services

ServiceDescriptionSource
Stem-cell bankingStorage of stem cellsInvesting.com profile
Analytical testingSample analysis for clinical studies; biopharmaceutical tests for identity, purity, potency and adventitious virusesInvesting.com profile

Financial Narrative

All figures are separate-basis K-IFRS from DART business reports, as compiled by ETF Shopping (updated 12 October 2026). The base unit is KRW 100M (억원), converted to KRW bn and rounded to one decimal. Quarterly figures are from DART quarterly and half-year reports. Figures reflect the latest-filed (amended) reports where the aggregator used them.

Income statement (FY2021–FY2025)

Notes:

  • Diluted EPS is NPD separately. With losses, diluted EPS equals basic.

  • No dividend has been declared in any year shown. The current dividend yield is 0.00% (ETF Shopping).

  • EBITDA and pre-tax income are NPD in the sources for FY2021–FY2025. The aggregator shows EBITDA only for FY2016 (KRW 0.3bn). Investing.com displays a trailing EBITDA of KRW 2.67bn, which is inconsistent with an operating loss of KRW 2.4bn and is treated as unreliable.

  • Revenue CAGR FY2021–FY2025: -1.9% (derived). FY2016–FY2025: +4.8% (derived).

Quarterly trajectory (Q1 2024–Q2 2026)

Notes:

  • The 2024 quarterly YoY growth figures were not provided by the source and are shown as 0 placeholders. Do not chart them.

  • H1 2026 revenue of KRW 4.3bn is up about 23% from KRW 3.5bn in H1 2025 (derived). The H1 2026 operating loss of KRW 1.6bn is flat year on year (derived).

  • The first Allostem shipments (July 2026) fall into Q3 2026, which is due for filing in mid-November 2026.

Source: DART business reports, compiled by ETF Shopping. FY2025 total payroll was KRW 1.1bn.

Sources: financialfilings.com (amended FY2025 annual report, filed 15 May 2026) for total assets, equity and CFO; Craft for cash and equivalents.

With only KRW 1.6bn in cash and equivalents against total assets of KRW 88.26bn, the bulk is presumably short-term financial instruments, the Magok R&D centre and plant (PP&E), and the EMtech equity stake. Investing.com shows book value per share of KRW 8,998 at an earlier date. Total debt (short- and long-term split), goodwill and intangibles, and working capital are NPD in the sources reviewed. The liability base of about KRW 0.8bn implies negligible financial debt.

Historical liquidity reference points.

  • H1 2018 report: cash-like assets including short-term financial assets of KRW 44.1bn (cash and equivalents KRW 20.1bn) (Dailypharm, Nov 2018).

  • February 2019: management cited about KRW 50bn of cash-like assets after the EMtech placement (Dealsite, Feb 2019).

Cash flow (FY2025)

Sources: financialfilings.com (CFO); ETF Shopping (FCF). No buyback or treasury-share programme was found (itooza shows no treasury-share ratio). FY2021–FY2024 cash flows are NPD in the sources reviewed.

Commentary on trends, inflections and drivers

Revenue. Revenue has been structurally flat for a decade. It moved between KRW 3.6bn and KRW 8.1bn from FY2016 to FY2025.

  • The FY2021 spike (+95.6% to KRW 8.1bn) was not explained in the sources reviewed.

  • From FY2023 revenue resumed modest single-digit growth: +6.7% in FY2024 and +8.7% in FY2025.

  • Quarterly growth accelerated to +32.5% in Q1 2026 and +16.5% in Q2 2026, before any Allostem contribution.

  • Because Remodulin is described as effectively the sole revenue source, the underlying growth driver through H1 2026 is most likely Remodulin volume. This is an inference, not a disclosure.

Gross margin. Gross margin has compressed steadily, from 71.5% in FY2016 and 47.7% in FY2021 to 35.3% in FY2025. This is consistent with a mix shift away from high-margin own cell therapies and cosmetics towards lower-margin distribution of an imported drug. Allostem supply should be margin-accretive if Anterogen captures a meaningful share of the Japanese insurance price. The transfer-price terms are not disclosed.

Operating losses.

  • Losses peaked in FY2023 (-KRW 5.1bn; -78.1% margin), when Korean and US DFU trials were running concurrently.

  • Losses have since narrowed to -KRW 2.4bn in FY2025 (-32.3% margin). The narrowing reflects trial completions (DFU-302 completed December 2024; the US Wagner 1 trial read out January 2025) and headcount reduction (43 to 29 between FY2022 and FY2024).

  • The Q1 losses (-KRW 1.1bn in both Q1 2025 and Q1 2026) look seasonal or one-off.

Net income versus operating income.

  • Net losses have consistently been smaller than operating losses (FY2025: -KRW 1.4bn versus -KRW 2.4bn), which indicates positive non-operating income.

  • FY2022 is the exception: the net loss (-KRW 6.8bn) exceeded the operating loss (-KRW 4.6bn), suggesting a non-operating charge such as a valuation loss on financial assets or merger-related items.

Balance sheet. The balance sheet is the company's principal financial strength. Equity of KRW 87.45bn against liabilities of about KRW 0.8bn gives roughly 60–80 years of runway at the FY2025 operating cash burn of about KRW 1.0bn. Dilution risk is therefore low unless a large US Phase 3 or capacity expansion is undertaken.

Restatement. The December 2025 amendments to four years of business reports, together with a further amendment to the FY2025 report in May 2026, are a governance and data-quality flag.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

CategoryContentsRevenue contributionTrendSource

Imported pharmaceuticals

Remodulin (treprostinil) injection, PAH

Largest; "effectively sole" revenue source

Stable to growing (inferred from total revenue growth)

Medisobizanews, Jun 2026

Cell therapy (own)

Cupistem; Queencell (withdrawn); Allostem supply (from Q3 2026)

Negligible through FY2025; Allostem adds from Q3 2026

Inflecting with Japan launch

Medisobizanews; Medical Daily

Cosmetics and raw materials

SCM2 line; Therastem line; stem-cell media

NPD

NPD

Investing.com profile

Services

Stem-cell banking; analytical testing

NPD

NPD

Investing.com profile

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

8.16.66.56.97.5

Cost of sales (KRW Bn)

4.24.03.84.34.9

Gross profit (KRW Bn)

3.92.62.72.62.7

Operating income (KRW Bn)

-2.6-4.6-5.1-3.7-2.4

Net income (KRW Bn)

-0.6-6.8-2.8-2.3-1.4

EPS basic (KRW)

-59-706-292-236-138

Dividends per share (KRW)

00000

Revenue growth YoY (%)

95.6-18.8-1.46.78.7

Gross margin (%)

47.739.741.037.935.3

Operating margin (%)

-32.3-70.5-78.1-54.1-32.3

Net margin (%)

-6.8-103.7-43.7-33.1-18.2

Income Statement and Margin Analysis (%)

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (KRW Bn)

4.95.43.64.14.2

Gross margin (%)

71.560.746.840.042.0

Operating income (KRW Bn)

0.1-0.1-2.4-2.9-3.7

Net income (KRW Bn)

0.40.4-1.0-4.0-4.4

EPS basic (KRW)

5057-114-470-481

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis

MetricQ1-24Q2-24Q3-24Q4-24Q1-25Q2-25Q3-25Q4-25Q1-26Q2-26

Revenue (KRW Bn)

1.51.71.91.81.61.92.02.02.12.2

Operating income (KRW Bn)

-1.0-0.9-0.6-1.3-1.1-0.5-0.4-0.5-1.1-0.5

Net income (KRW Bn)

-0.6-0.5-0.2-1.0-0.7-0.1-0.1-0.5-0.9-0.1

Revenue growth YoY (%)

00004.610.47.412.032.516.5

Operating Metrics (headcount) and Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Employees (headcount)

4143372932

Revenue per employee (KRW Mn)

200150180240240

Operating income per employee (KRW Mn)

-64-110-140-130-76

Payroll as % of revenue (%)

17.424.720.615.614.6

Average salary (KRW Mn)

34.537.836.237.334.3

Balance Sheet and Margin Analysis (%)

MetricFY2025

Total assets (KRW Bn)

88.26

Total equity (KRW Bn)

87.45

Total liabilities (KRW Bn, derived)

0.81

Cash and cash equivalents (KRW Bn)

1.6

Equity ratio (%, derived)

99.1

Liabilities-to-equity (%, derived)

0.9

Book value per share (KRW, derived at 10.01M shares)

8,737

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2025

Operating cash flow (KRW Bn)

-1.02

Free cash flow (KRW Bn)

-1.1

Capex (KRW Bn, derived)

0.1

Dividends paid (KRW Bn)

0

Share buybacks (KRW Bn)

0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025Note

ROE (%)

-1.6

ETF Shopping

ROA (%)

-1.6

ETF Shopping

Current ratio

NPD

—

Debt/equity

~0

Liabilities only ~0.9% of equity

Asset turnover (x, derived)

0.085

Revenue 7.54 / assets 88.26

Cash conversion cycle

NPD

—

Geographic Revenue

ItemFindingSource

Revenue by segment × geography

NPD

—

Geographic split (3 years)

NPD; revenue through FY2025 is understood to be predominantly domestic (Korea)

Inference from product mix (Medisobizanews)

Country-level revenue

NPD

—

Japan

First export revenue expected from Q3 2026 (1,400 sheets shipped July 2026; about KRW 2.5bn at Japanese insurance price, which is not Anterogen's revenue)

Medical Daily; withnews

Taiwan

Ishin holds Taiwan rights; no launch disclosed

Biotimes

US

No commercial revenue; Phase 2 programmes (EB, DFU Wagner 2)

Medisobizanews

Share Price History

DatePrice (KRW)ContextSource

3 Jan 2018

63,300

52-week high at the time

Financial News, Jan 2018

2 Aug 2021

92,700

Pre-DFU-301 readout high; market cap about KRW 873bn

Dailypharm, Aug 2021

30 Nov 2021

54,300

IR amid insider-sale controversy

Dailypharm, Dec 2021

3 Feb 2025

17,370

After the US Phase 2 failure (-21.4%)

Edaily, Feb 2025

Early Mar 2026

43,000

MHLW council date announced (+19.78%)

Biotimes

22 Jun 2026

24,400

52-week range 20,000–61,800

itooza

~20 Jul 2026

16,770

-8.41% on the day

Stockhub

21 Sep 2026

14,540—

Asiae ticker

15 Oct 2026

14,020

52-week low

ETF Shopping

Valuation Snapshot

MetricValueSource

1-month return (%)

-7.9

ETF Shopping, 15 Oct 2026

6-month return (%)

-62.4

ETF Shopping

1-year return (%)

-42.4

ETF Shopping

3-year and 5-year returns

NPD. From the 2 Aug 2021 high of KRW 92,700 the stock is down about 85% (derived)

Dailypharm; ETF Shopping

52-week high (KRW)

58,000 per ETF Shopping; 61,800 per itooza and Stockhub

Discrepancy noted

52-week low (KRW)

14,020 per ETF Shopping; 13,500 per Stockhub (July 2026 view)

Discrepancy noted

Valuation Multiples

MultipleAnterogenNote

Market cap (KRW Bn)

140.3

ETF Shopping

P/E (x)

n/m

Loss-making (EPS -KRW 138)

P/B (x)

1.60

ETF Shopping

P/S (x, derived)

18.6

140.3 / 7.54

EV/Sales

NPD

—

EV/EBITDA

n/m

Negative EBITDA

Share Count (thousand)

Metric2016201720192025

New shares issued (thousand)

700490210270

Analyst Conclusions

Management guidance

  • Quantitative guidance: none.

  • Japanese launch: achieved on 27 July 2026.

  • Expansion to two further countries in Asia and Europe.

  • ANT-301 Phase 2 start within 2026; US IND under review.

  • ANT-501 Phase 1 IND targeted for 2026.

  • US EB Phase 2 continuing.

(Medical Daily, Jul 2026; Medisobizanews, Jun 2026; IR, Mar 2026.)

Consensus

No sell-side consensus exists (Stockhub: 0 reports).

Bull case

  1. Allostem economics. At a Japanese insurance price of about JPY 2.96M per set, the 1,400-sheet launch shipment alone was valued at about KRW 2.5bn at insurance prices, roughly one-third of Anterogen's entire FY2025 revenue (KRW 7.5bn). Even a modest share of Japan's 500–1,000 EB patients, through supply revenue plus a royalty of about 9%, could transform the income statement and lift gross margin from its 35.3% FY2025 level.

  2. Balance-sheet optionality. Equity of KRW 87.45bn and negligible liabilities give the company the capacity to fund the US EB programme and ANT-301 Phase 2 without near-term dilution. At about 1.6x book, downside is partly anchored by net assets.

  3. Label and format advantage. The three-subtype EB label and the off-the-shelf format differentiate Allostem from the DEB-only gene therapy and from autologous grafts. A US Phase 2 success under orphan designation would open a market where the leading DEB product earned USD 389.1M in FY2025.

Bear case

  1. Platform credibility. DFU-301 failed in Korea, and the US Wagner 1 Phase 2 showed the active arm numerically worse than control (45.7% vs 60%). DFU-302 data remain unreported more than 21 months after primary completion. The EB success may be indication-specific rather than evidence that the platform works broadly.

  2. Commercial execution history. Queencell was withdrawn and Cupistem sales are negligible despite reimbursement. Revenue depends on an imported PAH drug, and gross margin has fallen for a decade. Japanese uptake is in the licensee's hands, and the patient pool is tiny.

  3. Governance and overhang. Four years of amended business reports, a history of insider and major-holder selling around catalysts, and EMtech's KRW 16.5bn bond exchangeable into Anterogen shares create disclosure and supply risks. These help explain why the stock fell about 75% from its 52-week high despite the approval.

Catalysts and monitorables (next 12 months)

Expected timingItemWhy it matters
Mid-November 2026Q3 2026 reportFirst period including Allostem shipments; reveals the transfer price and margin
OngoingReorder cadence and volume from IshinThe true demand signal, as opposed to the launch stocking order
2026–2027DFU-302 topline disclosureFate of the DFU franchise
2,026US IND clearance and Phase 2 start for ANT-301Second leg of the cell-therapy platform
2,026ANT-501 Phase 1 INDDiversification beyond cell therapy
NPDUS EB Phase 2 progressPath to the largest EB market
NPDTaiwan or other filings by Ishin; additional country dealsGeographic expansion
OngoingEMtech EB exchange activity and large-holding filingsShare-supply overhang
March 2027FY2026 business reportAbsence of further amendments would signal improved disclosure quality

Analyst verdict

Anterogen has reached the point every cell-therapy developer aims for: a regulator-approved, reimbursed product in a demanding market, manufactured in its own accredited plants and shipped commercially. The Japanese approval of Allostem in April 2026 validates the off-the-shelf allogeneic ASC sheet as a product. It is a genuine first for a Korean stem-cell developer.

Yet the market has treated the approval as the end of a story rather than the start of one. The share price fell from a 52-week high of KRW 58,000–61,800 to KRW 14,020 within roughly six months. At about 1.6x book and roughly 19x trailing sales, the market is pricing Allostem as a niche orphan product with uncertain economics and is assigning little value to the rest of the pipeline.

That scepticism is evidence-based. The company's own record shows:

  • Two domestic products that never scaled.

  • Revenue that has been flat around KRW 4–8bn for a decade and depends on an imported drug.

  • Two failed DFU efficacy readouts.

  • Repeated governance blemishes, including restated filings.

Against this, the balance sheet is exceptionally clean, the burn is small, and the Japanese price point is high enough that even dozens of treated patients would be material to a company of this size.

Verdict. Anterogen is a high-uncertainty, catalyst-dependent special situation, not a compounding growth franchise. The key variable over the next 12 months is the Q3 and Q4 2026 revenue lines: the first transparent read of Allostem's transfer price, gross margin and reorder frequency. Positive revisions to Japanese uptake, a disclosed and favourable DFU-302 outcome, or US progress in EB or ANT-301 could justify a re-rating towards prior levels. Absent those, the stock is likely to trade near net asset value while the market waits for proof that Anterogen can convert regulatory success into durable commercial revenue, something its history has not yet demonstrated.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundShareholdingSource

Lee Sung-gu (이성구)

Co-CEO, representative director; founder; largest shareholder

Founded Anterogen in 2000 while a Bukwang Pharmaceutical executive; Bukwang CEO 2004–2013 while also leading Anterogen. Education and age NPD

12.16%

DART FY2025; Dealsite, Jan 2019

Kim Mi-hyung (김미형)

Co-CEO, representative director

Co-CEO since Mar 2018; public face of Japan approval and commercialisation communications (2023–2026). Education and age NPD

0.87%

DART FY2025; Jobplanet; Hankyung

Kim In-ok (김인옥)

Executive; Head of Research Institute

Head of research institute (cited 2018)

0.37%

DART FY2025; Dailypharm, Nov 2018

Lee Tae-hee (이태희)

Executive

NPD

0.11%

DART FY2025

Ryu Hong-gi (류홍기)

Executive

NPD

0.02%

DART FY2025

Workforce Metrics

MetricFY2025Source

Average pay per director/auditor (KRW Mn)

110

DART FY2025 (6 persons)

Ratio to average employee pay (x)

3.3

ETF Shopping (derived)

Individuals paid ≥ KRW 500M

None disclosed

DART individual-disclosure threshold

Major Shareholders

HolderRelationshipStake (%)Source

Lee Sung-gu

Largest shareholder

12.16

DART FY2025

Jang Wan-soon

Relative

0.90

DART FY2025

Kim Mi-hyung

Executive

0.87

DART FY2025

Kim In-ok

Executive

0.37

DART FY2025

Lee Tae-hee

Executive

0.11

DART FY2025

Lee Hye-mi

Relative

0.10

DART FY2025

Lee Young-jae

Relative

0.04

DART FY2025

Kwon Mi-sun

Relative

0.03

DART FY2025

Ryu Hong-gi

Executive

0.02

DART FY2025

Largest shareholder + related parties

—

14.60

DART FY2025

EMtech Co., Ltd.

5%+ holder (report dated 21 Apr 2026)

7.25

Large-holding report

Minority shareholders (12,965 holders)

—71.28

DART FY2025

Metric

FY2021

FY2022

FY2023

Largest shareholder + related parties stake (%)

14.3415.0315.03

Competitive Landscape

Competitors by Segment

AreaCompetitorProduct / approachRelative positioningSource / note

EB (Japan and global)

Krystal Biotech (US)

Vyjuvek (B-VEC), topical redosable HSV-1 gene therapy for DEB; approved in the US (2023) and in Japan and Europe (2025)

Incumbent DEB leader; FY2025 Vyjuvek net revenue USD 389.1M; 94% gross margin. DEB only, whereas Allostem's Japanese label also covers JEB and severe EBS

Krystal 8-K, Feb 2026

EB (Japan)

Japan Tissue Engineering (J-TEC)

Autologous cultured epidermis for EB

Autologous (needs a patient biopsy and culture); Allostem is off-the-shelf

Daily Invest (Kiwoom commentary)

EB (global)

Abeona Therapeutics (US)

Autologous gene-corrected keratinocyte sheets (pz-cel) for RDEB

Surgical grafting; US-focused

—

EB (global)

Chiesi

Topical birch-bark extract gel for EB wounds

Supportive wound therapy

—

Crohn's fistula

Takeda

Darvadstrocel (allogeneic ASC)

Direct mechanistic analogue to Cupistem and ALLO-ASC-CD

—

Korean cell therapy

Medipost

Cartistem (umbilical-cord MSC, cartilage)

Larger Korean MSC player; competes with ANT-301 in knee OA

Biospectator, 2014

Korean cell therapy

Pharmicell

Cellgram-AMI (bone-marrow MSC, acute MI)

Early Korean approval peer

PMC review; Biospectator

Korean cell therapy

CHA Biotech

Cell-therapy platforms

Listed on THE VC as a similar company

THE VC

Korean cell therapy

Hurim Biocell

Cell therapy

Listed on THE VC as a similar company

THE VC

Korean cell therapy

Corestem, Tego Science, Kangstem Biotech, S.Biomedics

Various MSC and tissue products

Domestic peers for capital and talent

General industry knowledge; financials NV

DFU / wound care

Advanced wound-care incumbents (bioengineered skin substitutes, amniotic membranes, growth-factor products)

Established standard-of-care adjuncts

Anterogen's DFU programme has failed twice; no competitive position yet

IR (amnion comparison study, 2021)

Herpes zoster

Acyclovir, valacyclovir and famciclovir (generic); recombinant zoster vaccines for prevention

Standard-of-care antivirals and vaccines

ANT-501 is preclinical

Company IR, 2023/2026

Peer Comparison FY2025

MetricAnterogen (FY2025)Krystal Biotech (FY2025)MedipostTakeda (darvadstrocel)

Revenue (local currency, M)

7,540389.1

NV

NV

Revenue currency

KRW

USD

——

Revenue growth (%)

8.7

NV

NV

NV

Gross margin (%)

35.394

NV

NV

Operating margin (%)

-32.3

NV

NV

NV

R&D intensity (%)

NPD

NV

NV

NV

Company Snapshot

$5.3M

Revenue

35

Employees

2000

Founded

SWOT Analysis

Strengths

  • Japanese approval secured. MHLW approval on 3 April 2026 made Allostem the first Korean-developed stem-cell therapy approved in Japan (Hankyung, Apr 2026).
  • Broad label. DEB, JEB and severe EBS, against a DEB-only incumbent, which the company says means a 68% larger addressable population (IR, Mar 2026).
  • Premium pricing. The Japanese insurance price is about JPY 2.96M per two-vial set (IR, Mar 2026).
  • Manufacturing readiness. PMDA Foreign Manufacturer Accreditation for both plants (March 2025), and a first shipment of 1,400 sheets within about 3.5 months of approval (Medical Daily, Jul 2026).
  • Balance sheet. Equity of KRW 87.45bn against total assets of KRW 88.26bn; liabilities about KRW 0.8bn (FY2025 annual report).
  • Regulatory pedigree. Two Korean approvals (Queencell 2010; Cupistem 2012, the world's first approved ASC product) (MFDS).

Weaknesses

  • Revenue concentration. Remodulin, an imported drug, is effectively the only revenue source (Medisobizanews, Jun 2026).
  • Persistent losses. Operating losses every year since FY2017; FY2025 operating margin -32.3% (DART).
  • Margin erosion. Gross margin fell from 71.5% (FY2016) to 35.3% (FY2025) (DART).
  • DFU failures. Korean Phase 3 DFU-301 failed (January 2022); US Phase 2 Wagner 1 failed with the active arm numerically worse than control (45.7% vs 60%) (Edaily).
  • Commercial execution record. Queencell withdrawn (2026); Cupistem sales negligible despite reimbursement (Medisobizanews).
  • Disclosure quality. Four years of business reports amended in December 2025; DFU-302 results not publicly reported more than 21 months after primary completion (irgo; ClinicalTrials.gov).

Opportunities

  • Japanese ramp. Supply margin and a royalty (about 9% of sales, per 2019 press) on a high-priced orphan therapy (eToday, 2019).
  • Geographic expansion. Two further countries in Asia and Europe are planned; Ishin holds Taiwan rights (Medical Daily; Biotimes).
  • US EB Phase 2 with FDA orphan designation; a US approval would open the largest EB market, where Vyjuvek earned USD 389.1M in FY2025 (Krystal 8-K).
  • ANT-301. Positive Phase 1 safety (August 2026); US IND under review; Phase 2 in 2026 (Kormedi; Medisobizanews).
  • DFU Wagner 2. DFU-302 (Korea) and DFU-103 (US) remain potential salvage paths, and RMAT designation would support a US route if the data are positive (IR, 2020).
  • Non-dilutive funding. 12 national R&D projects (THE VC).

Threats

  • Gene-therapy competition. Vyjuvek launched in Japan in 2025, with more than 90 patients prescribed across Germany, France and Japan by year-end 2025 (Krystal 8-K, Feb 2026).
  • Licensee dependence. Ishin controls Japanese pricing, market access and reporting.
  • Share overhang. EMtech's KRW 16.5bn bond exchangeable into Anterogen shares (Bizwatch, Apr 2026).
  • Sentiment and valuation volatility. Shares fell from a 52-week high of KRW 58,000–61,800 to KRW 14,020 (ETF Shopping; itooza).
  • Japanese price revisions. Periodic NHI repricing could compress economics (structural risk; no specific action identified).
  • Small patient pool. Japanese EB prevalence of about 500–1,000 caps peak revenue (Hankyung).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Jan 2025US Phase 2 (Wagner grade 1 DFU) topline misses primary endpoint (45.7% vs 60% complete closure) Edaily, Feb 2025Second DFU efficacy failure; undermines the DFU franchise
3 Feb 2025Shares fall 21.4% to KRW 17,370 Edaily, Feb 2025Market de-rates DFU value
10 Feb 2025Board approves issuance of 270,000 new shares DART via ETF ShoppingAbout 2.8% dilution
10 Mar 2025PMDA Foreign Manufacturer Accreditation for the Gasan and Magok plants announced Hankyung, Mar 2025Prerequisite for Japanese supply
11 Mar 2025Ishin's pre-NDA meeting with PMDA announced (expected 16 Apr 2025) Hankyung, Mar 2025Japanese filing path confirmed
13 Mar 2025FY2024 business report filed (revenue KRW 6.9bn; operating loss KRW 3.7bn) DARTNarrowing losses
21 Mar 2025AGM held at the Magok Central Research Institute; clinical and regulatory update Hankyung, Mar 2025Shareholder communication
15 May 2025Q1 2025 report (revenue KRW 1.6bn; operating loss KRW 1.1bn) DART—
30 Jun 2025Company announces that Ishin will file the Japanese NDA for ALLO-ASC-EB Daily InvestRegulatory catalyst
8 Jul 2025Ishin files the NDA with MHLW/PMDA with an expanded label (DEB, JEB, EBS) Biotimes; Daily InvestLabel broader than the DEB-only competitor
8 Jul 2025Co-CEO Kim Mi-hyung expects an approval decision within about 9 months under orphan status Hankyung, Jul 2025Timeline guidance (proved accurate)
Jul 2025Kiwoom Securities analyst expects a Japanese launch at the end of 1H or early 2H 2026 Daily InvestSell-side view
14 Aug 2025Q2 2025 report (revenue KRW 1.9bn; operating loss KRW 0.5bn) DARTSharp loss reduction
14 Nov 2025Q3 2025 report (revenue KRW 2.0bn; operating loss KRW 0.4bn) DARTLowest quarterly loss in the period
3 Dec 2025Management says it has passed the "90% mark" towards approval; PMDA plant inspection due that month Hankyung, Dec 2025De-risking
22 Dec 2025Amended business reports filed for FY2021–FY2024 and the 2025 quarters irgoGovernance and data-integrity flag
Early Mar 2026 (date approximate)Company says the MHLW council (regenerative medicine products / biological technology subcommittee) will deliberate on 9 Mar 2026; shares rise 19.78% to KRW 43,000 BiotimesApproval visibility
9 Mar 2026MHLW council deliberation; reported as passed Chickstock IR summaryPre-approval step cleared
12 Mar 2026FY2025 business report filed (revenue KRW 7.5bn; operating loss KRW 2.4bn) DART—
16 Mar 2026IR presentation: insurance price about JPY 2.96M per set; addressable population said to be 68% larger than the competitor's; ANT-301 and ANT-501 updates Chickstock IR summaryCommercial parameters disclosed
3 Apr 2026MHLW grants marketing approval for Allostem, the first Korean-developed stem-cell therapy approved in Japan Hankyung, Apr 2026Landmark validation
8 Apr 2026Approval confirmed via official gazette notice (No. 179). The company did not file a KRX disclosure after the exchange advised one was not required Hankyung, Apr 2026Disclosure-practice note
21 Apr 2026EMtech files a 7.25% large-holding report DART via ETF ShoppingStrategic holder visibility
24 Apr 2026EMtech issues a KRW 16.5bn zero-coupon bond exchangeable into Anterogen shares Bizwatch, Apr 2026Potential share overhang
15 May 2026Q1 2026 report (revenue KRW 2.1bn, +32.5% YoY; operating loss KRW 1.1bn) and amended FY2025 business report DARTRevenue acceleration
~15 Jun 2026Queencell marketing authorisation withdrawn Medisobizanews, Jun 2026Legacy-product exit
22 Jun 2026Share price KRW 24,400 (market cap about KRW 244bn); 52-week range KRW 20,000–61,800 itoozaSteep post-approval drawdown
10 Jul 2026Substantial-shareholding report filed (filer NV) financialfilings.comOwnership change
13–14 Jul 2026First commercial shipment: 1,400 sheets to Ishin (about KRW 2.5bn at Japanese insurance price) Medical DailyFirst export revenue from Q3 2026
~20 Jul 2026Shares fall 8.41% to KRW 16,770 (date approximate; aggregator timestamp) StockhubContinued de-rating
27 Jul 2026Allostem launched in Japan Medical Daily; withnewsCommercial start
4 Aug 2026ANT-301-102 Phase 1 (knee OA, K-L 3–4) confirms safety in 6 subjects Kormedi AI disclosure feedPipeline progress
14 Aug 2026Q2 2026 report (revenue KRW 2.2bn, +16.5% YoY; operating loss KRW 0.5bn; net loss KRW 0.1bn) DARTPre-Allostem baseline
21 Sep 2026Share price KRW 14,540 (-3.96% on the day) Asiae tickerNear 52-week low
15 Oct 2026Close KRW 14,020: 52-week low; -42.4% over 1 year; -62.4% over 6 months ETF ShoppingValuation reset

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

2 charts
Income Statement (FY2021–FY2025): Revenue fell from KRW 8,100 Mn in FY2021 to KRW 7,500 Mn in FY2025.
Anterogen.Co., Ltd. — Income Statement (FY2021–FY2025)
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue8,1006,6006,5006,9007,500
Cost of sales4,2004,0003,8004,3004,900
Gross profit3,9002,6002,7002,6002,700
Operating income-2,600-4,600-5,100-3,700-2,400
Net income-600-6,800-2,800-2,300-1,400
Revenue per employee200150180240240
Operating income per employee-64-110-140-130-76
Average salary34.537.836.237.334.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ETF Shopping — Anterogen financials, earnings and company data compiled from DART (accessed Oct 2026) · etfshopping.com · etfshopping.com
  2. financialfilings.com — Anterogen FY2025 key figures (amended annual report, 15 May 2026) (financialfilings.com)
  3. irgo — Anterogen filing and IR list (m.irgo.co.kr)
  4. MFDS (English) — Cupistem and Queencell product information (mfds.go.kr)
  5. ClinicalTrials.gov — NCT04569409; NCT03370874; NCT06141811; NCT04590703; NCT02619851
  6. Hankyung — Allostem Japanese approval (3 Apr 2026) · gazette listing (8 Apr 2026) · PMDA inspection (Dec 2025) · FMA and pre-NDA (Mar 2025) · NDA filing (Jul 2025) · 2023 outlook
  7. Medical Daily — first Allostem export (Jul 2026) (medicaldaily.co.kr)
  8. withnews — Allostem shipment and launch (Jul 2026) (car.withnews.kr)
  9. Medisobizanews — Queencell withdrawal and business-structure analysis (15 Jun 2026) (medisobizanews.com)
  10. Chickstock — summary of the 16 Mar 2026 IR (chickstockfi.com)
  11. Biotimes — MHLW council date and share move (biotimes.co.kr)
  12. Daily Invest — Kiwoom commentary on the Japanese filing (Jul 2025) (dailyinvest.kr)
  13. Edaily — US Phase 2 failure (Feb 2025) · DFU-301 failure (Jan 2022)
  14. Dailypharm — DFU programme, Bukwang disposals, insider sales (2018–2023) · dailypharm.com · dailypharm.com · m.dailypharm.com · dailypharm.com · dailypharm.com
  15. Bizwatch — CSK merger and DFU failure (Jan 2022) · EMtech exchangeable bond (Apr 2026)
  16. Biospectator — Ishin licences and strategy · biospectator.com · biospectator.com · biospectator.com
  17. Dealsite — Bukwang sell-down and EMtech placement · dealsite.co.kr · dealsite.co.kr
  18. Medical Times — Cupistem NDA (Sep 2011) (medicaltimes.com)
  19. Kormedi — ANT-301-102 disclosure feed (Aug 2026) (kormedi.com)
  20. itooza — price and listing data (itooza.com)
  21. Stockhub — price and coverage data (stockhub.kr)
  22. Investing.com — company profile and ISIN · m.uk.investing.com
  23. Simply Wall St (simplywall.st)
  24. Craft (craft.co)
  25. THE VC (thevc.kr)
  26. PatSnap Discovery (discovery.patsnap.com)
  27. Jobplanet company history (jobplanet.co.kr)
  28. Company IR decks (2019–2023) via Alphasquare (file.alphasquare.co.kr)
  29. PMC review of approved MSC products (pmc.ncbi.nlm.nih.gov)
  30. Krystal Biotech FY2025 8-K / results (ir.krystalbio.com)
  31. Korea Herald — patent disclosure (Oct 2016) (koreaherald.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.